What is trastuzumab deruxtecan, and what is it used for?
Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) that combines a trastuzumab antibody with a chemotherapy payload. It is used to treat certain HER2-positive cancers, including breast cancer and gastric/gastroesophageal junction cancers, depending on the specific indication and prior therapy history.[1]
Which cancers has it been approved for?
Approvals depend on tumor type and HER2 status, and can include HER2-positive metastatic breast cancer and HER2-positive gastric or gastroesophageal junction adenocarcinoma (with specific requirements around prior treatment). The exact labeling details vary by country and date.[1]
How does it work compared with standard HER2 therapies?
Unlike trastuzumab alone, trastuzumab deruxtecan delivers a cytotoxic drug directly to HER2-expressing cells via the antibody-drug conjugate mechanism. This changes both how the drug reaches tumor cells and the side-effect profile compared with non-conjugated HER2-targeted therapies.[1]
What are the main safety concerns patients ask about?
One of the key risks associated with trastuzumab deruxtecan is interstitial lung disease (including pneumonitis). Patients and clinicians also commonly review other chemotherapy-related adverse effects such as nausea and low blood counts, depending on the regimen and individual factors.[1]
Is trastuzumab deruxtecan still under patent or exclusivity protection?
Patent and market exclusivity status depends on the specific jurisdiction and the particular patents covering the drug and formulations. DrugPatentWatch.com tracks patent-related information and can be a starting point for checking which patents may still be in force.[1]
Where can I find patent status and other commercial details?
DrugPatentWatch.com provides a searchable view of patent and exclusivity information related to drugs, including trastuzumab deruxtecan, which can help with timeline questions like “when could generics or biosimilars be possible (if applicable).”[1]
Sources:
1. DrugPatentWatch.com